Viridian Therapeutics (VRDN) announced that the FDA has accepted the biologics license application for veligrotug for the treatment of thyroid eye disease. The application has been granted priority review, with a Prescription Drug User Fee Act target action date of June 30, 2026. Preparations are underway for veligrotug’s anticipated commercial launch. The company also plans to submit a marketing authorization application to the European Medicines Agency in the first quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- 3 Stocks Flashing Strong Buy Signals, Backed by Technical Analysis
- Viridian Therapeutics: Strong Market Position and Promising Catalysts Justify Buy Rating
- Viridian Therapeutics Positioned for Growth in TED Market Amidst Competitive Setbacks
- Argenx exit leaves more room for Viridian in TED, says Truist
- Viridian Therapeutics rises 5.0%